These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37356143

  • 1. The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
    Roh J, Pak HK, Jeong S, Hwang S, Kim DE, Choi HS, Kim SJ, Kim H, Cho H, Park JS, Jeong SH, Choi YS, Han JH, Yoon DH, Park CS.
    Biochem Biophys Res Commun; 2023 Sep 17; 673():36-43. PubMed ID: 37356143
    [Abstract] [Full Text] [Related]

  • 2. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.
    J Clin Oncol; 2012 Oct 01; 30(28):3452-9. PubMed ID: 22851565
    [Abstract] [Full Text] [Related]

  • 3. BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.
    Roh J, Cho H, Pak HK, Lee YS, Lee SW, Ryu JS, Chae EJ, Kim KW, Huh J, Choi YS, Jeong SH, Suh C, Yoon DH, Park CS.
    Mod Pathol; 2022 Apr 01; 35(4):480-488. PubMed ID: 34764434
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH.
    Haematologica; 2013 Feb 01; 98(2):255-63. PubMed ID: 22929980
    [Abstract] [Full Text] [Related]

  • 11. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, German High-Grade Non-Hodgkin Lymphoma Study Group.
    Blood; 2013 Mar 21; 121(12):2253-63. PubMed ID: 23335369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J, Liu JL, Medeiros LJ, Huang W, Khoury JD, McDonnell TJ, Tang G, Schlette E, Yin CC, Bueso-Ramos CE, Lin P, Li S.
    Eur J Haematol; 2020 Apr 21; 104(4):336-343. PubMed ID: 31944390
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
    Johnson PWM, Balasubramanian S, Hodkinson B, Shreeve SM, Sun S, Srinivasan S, Steele AJ, Vermeulen J, Sehn LH, Wilson WH.
    Blood Adv; 2023 May 23; 7(10):2008-2017. PubMed ID: 36696540
    [Abstract] [Full Text] [Related]

  • 18. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
    Gong QX, Lu TX, Liu C, Wang Z, Liang JH, Xu W, Li JY, Zhang ZH, Chen Q.
    Int J Clin Exp Pathol; 2015 May 23; 8(12):15825-35. PubMed ID: 26884853
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 20. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP, Mihaljevic B, Jakovic L, Martinovic VC, Fekete MD, Andjelic B, Antic D, Bogdanovic A, Boricic N, Terzic T, Jelicic J, Milenkovic S.
    J BUON; 2015 Sep 01; 20(3):820-8. PubMed ID: 26214636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.